Evidence map›Paper›PMID 41824881›Full record

ArticleMedicine2026

Machine learning diagnostic framework for liver fibrosis in chronic hepatitis B based on routine laboratory tests.

Li Hou, Jing Tang, Wenli He, Wenpei Qin

Abstract read
In one paragraph

Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Li HouMedical Laboratory Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.ORCID 0009-0009-6748-4314
Jing Tang
Wenli He
Wenpei Qin

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early detection of liver fibrosis in chronic hepatitis B (CHB) patients is crucial for improving their prognosis. This study aims to develop a machine learning (ML)-based diagnostic model for evaluating the degree of liver fibrosis in patients with CHB. The present study comprised 268 patients with CHB who underwent liver biopsy from January 2022 to May 2023. Liver fibrosis was staged according to the Scheuer scoring system. The dataset is divided into a training set and a validation set in a ratio of 7.5:2.5. The feature selection process was executed through the utilization of least absolute shrinkage and selection operator regression, and 8 ML algorithms (including random forest [RF], extreme gradient enhancement, support vector machine, etc) were employed for the prediction of the performance of the significant liver fibrosis assessment model. The RF model performs best among ML models, with an area under the curve value of 0.810 for the training set and 0.793 for the validation set. Decision curve analysis indicates that the RF model exhibits the highest net benefit under most threshold probabilities. When the probability threshold is 30%, the sensitivity and net benefit are the highest, significantly outperforming other traditional scores. RF ML models can effectively assess liver fibrosis in patients with CHB. Compared with traditional indicators, they can become a safe, effective and more personalized screening method, enabling early and dynamic risk decision-making.

Indexed as

Hepatitis B, ChronicLiver CirrhosisMachine LearningAdultAlgorithmsBiopsyClassification AlgorithmsFemaleHumansLiverMaleMiddle AgedPredictive Learning ModelsRandom Forestchronic hepatitis Bdiagnostic modelliver fibrosismachine learningrandom forest

Identifiers

PMID41824881
PMCPMC12991754

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.